NCT01573533View on ClinicalTrials.gov

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 15, 2018

Study Completion Date

November 15, 2018

Conditions
Primary Focal Segmental Glomerulosclerosis
Interventions
BIOLOGICAL

Rituximab

Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.

Trial Locations (4)

55905

Mayo Clinic College of Medicine, Rochester

60612

Rush University Medical Center, Chicago

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2N2

University Health Network, Toronto

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

University Health Network, Toronto

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Rush University Medical Center

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER